Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

My Type 2 Diabetes: Person-centred Health Care (MinT2D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04935554
Recruitment Status : Recruiting
First Posted : June 23, 2021
Last Update Posted : June 23, 2021
Sponsor:
Collaborators:
The Centre for Health Innovation
The Dam Foundation
Information provided by (Responsible Party):
Norwegian University of Science and Technology

Brief Summary:
The T2D project is a research and innovation project that will create a new comprehensive, participant-centered service model for interaction, increased physical activity, self-management, distance monitoring and lifestyle change for patients with type 2 diabetes (T2D). Central to the degree of innovation is a new model for interaction and use of technology for distance monitoring and coping.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Other: Person centred care Not Applicable

Detailed Description:

Type 2 diabetes is both physically and mentally stressful. At the same time, it requires a high individual effort, which can be demanding. Good mental health is necessary to be able to manage and control diabetes in a healthy and effective way. Therefore, we want to create an offer that takes care of the whole person, and physically as well as mentally.

Personal follow-up Based on surveys and conversations, the study participant and a contact person will prepare a 12-week plan that will be implemented with self-measurements and follow-up from the contact person. The plan will consist of the activities that best suit the participant's needs. It can be physical activity, diet course, health competence, motivation and psychosocial intervention that will be useful for the participant. After 12 weeks, the implementation will be evaluated.

Several new technological solutions are developed and will be used during the project period. A digital tool for mapping of the individuals needs will be an important part of the survey that is done during start-up. Activity clocks will be used for measuring steps, heart rate, and number of PAI. An online portal for communication and interaction will make information easily accessible to users, simplify distance follow-up and communication flow.

The intervention will take place at two Healthy Life Centres (HLC). A HLC is an interdisciplinary primary health care service which offers effective, knowledge-based measures for people with, or in high risk of disease, who need support in health behaviour change and in coping health problems and chronic disease.

The HLC is part of the public health care service in the municipality. HLC programs have a patient centred approach and aim at strengthening the individual's control of his or her own health.

The intervention study starts in two municipalities in Møre og Romsdal, and the goal is to make the offer national.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: My Type 2 Diabetes: Person-centred Health Care
Actual Study Start Date : August 17, 2020
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Intervention
Baseline testing with blood samples, blood pressure and 6 minute walking test. After answering a comprehensive screening tool questionnaire and a conversation with a resource person about "What is important to you", the study participant will chose one or several of the following interventions: physical activity, nutrition, motivation, health competence, psychosocial.
Other: Person centred care
physical activity, nutrition, motivation, health competence, psychosocial.

No Intervention: Control
Baseline testing with blood samples, blood pressure, 6 minute walking test and screening tool questionnaire.



Primary Outcome Measures :
  1. Change in HbA1c from baseline until week 12 [ Time Frame: Baseline and week 12 ]
    Glycated haemoglobin (HbA1c) is a measurement of the three-month average blood sugar level and HbA1c is an important outcome measure in diabetes clinical trials.


Secondary Outcome Measures :
  1. Change in waist circumference from baseline until week 12 [ Time Frame: Baseline and week 12 ]
    Waist circumference is a simple method to assess abdominal adiposity that is easy to standardize and clinically apply. Waist circumference is strongly associated with all-cause and cardiovascular mortality

  2. Change in physical fitness by the number of PAI from baseline until week 12 [ Time Frame: Baseline and week 12 ]
    PAI (personalized activity index) was derived from an algorithm from one of the world's largest health studies (HUNT) and is a single, easy-to-understand personalized activity tracking metric that can help everyday people manage their health. Maintaining 100 PAI or more per week is strongly associated with adding on average 5 years to your life and reducing the risk of cardiovascular disease mortality by an average of 25%.

  3. Health competence [ Time Frame: Baseline and week 12 ]
    HLS-Q12 short version of the European Health Literacy Survey Questionnaire (HLS-EU-Q47)

  4. Change in mental health by questionnaire SCL-90r until week 12 [ Time Frame: Baseline and week 12 ]
    The Symptom Checklist-90-R (SCL-90-R) is a relatively brief self-report psychometric instrument (questionnaire) published by the Clinical Assessment division of the Pearson Assessment & Information group. It is designed to evaluate a broad range of psychological problems and symptoms of psychopathology. SCL-90r is useful in measuring patient progress or treatment outcomes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

• Type 2 diabetes

Exclusion Criteria:

  • Unstable cardiovascular disease
  • Severe chronic obstructive pulmonary disease (COPD)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04935554


Contacts
Layout table for location contacts
Contact: Charlotte Ingul, PhD +4795805886 charlotte.b.ingul@ntnu.no
Contact: Bjarte Løfaldli, PhD +4747503051 bjarte.lofaldli@helseinnovasjonssenteret.no

Locations
Layout table for location information
Norway
Department of Circulation and Medical Imaging, NTNU Recruiting
Trondheim, Norway
Contact: Charlotte Ingul, PhD         
Sponsors and Collaborators
Norwegian University of Science and Technology
The Centre for Health Innovation
The Dam Foundation
Investigators
Layout table for investigator information
Principal Investigator: Charlotte Ingul, PhD Norwegian University of Science and Technology
Layout table for additonal information
Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT04935554    
Other Study ID Numbers: 123998
First Posted: June 23, 2021    Key Record Dates
Last Update Posted: June 23, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases